Associate Professor Stanko Skrtic

Soborg (Sweden)

Membership: ESC Professional Member

Follow

Contributor content

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

Presentation

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

ESC 365 is supported by

novartis

Explore sponsored resources